2INV Fundamental Analysis - 2INVEST AG

Fundamental Rating

Overall 2INV gets a fundamental rating of 4 out of 10. We evaluated 2INV against 83 industry peers in the Biotechnology industry. 2INV is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. 2INV has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year 2INV was profitable.

In the past year 2INV has reported a negative cash flow from operations.

The reported net income has been mixed in the past 5 years: 2INV reported negative net income in multiple years.

In multiple years 2INV reported negative operating cash flow during the last 5 years.

1.2 Ratios

2INV has a Return On Assets of 29.93%. This is amongst the best in the industry. 2INV outperforms 96.39% of its industry peers.

2INV has a better Return On Equity (30.46%) than 92.77% of its industry peers.

With an excellent Return On Invested Capital value of 22.40%, 2INV belongs to the best of the industry, outperforming 97.59% of the companies in the same industry.

Measured over the past 3 years, the Average Return On Invested Capital for 2INV is in line with the industry average of 12.28%.

The 3 year average ROIC (11.84%) for 2INV is below the current ROIC(22.40%), indicating increased profibility in the last year.

		Industry Rank	Sector Rank
ROA	29.93%
ROE	30.46%
ROIC	22.4%

ROA(3y)-1.72%

ROA(5y)11.4%

ROE(3y)-1.65%

ROE(5y)11.58%

ROIC(3y)11.84%

ROIC(5y)16.55%

1.3 Margins

2INV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

2INV has less shares outstanding than it did 1 year ago.

Compared to 5 years ago, 2INV has less shares outstanding

2INV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

2INV has an Altman-Z score of 23.54. This indicates that 2INV is financially healthy and has little risk of bankruptcy at the moment.

2INV has a better Altman-Z score (23.54) than 95.18% of its industry peers.

2INV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	23.54

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

2INV has a Current Ratio of 41.87. This indicates that 2INV is financially healthy and has no problem in meeting its short term obligations.

2INV has a better Current ratio (41.87) than 100.00% of its industry peers.

A Quick Ratio of 41.87 indicates that 2INV has no problem at all paying its short term obligations.

2INV has a Quick ratio of 41.87. This is amongst the best in the industry. 2INV outperforms 100.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	41.87
Quick Ratio	41.87

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

2INV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 415.47%, which is quite impressive.

EPS 1Y (TTM)415.47%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%231.05%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 2.59, the valuation of 2INV can be described as very cheap.

Compared to the rest of the industry, the Price/Earnings ratio of 2INV indicates a rather cheap valuation: 2INV is cheaper than 97.59% of the companies listed in the same industry.

2INV's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.56.

		Industry Rank	Sector Rank
PE	2.59
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

2INV does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

2INVEST AG

FRA:2INV (12/12/2025, 7:00:00 PM)

11.7

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-13 2025-08-13

Earnings (Next)02-26 2026-02-26

Inst Owners0.35%

Inst Owner ChangeN/A

Ins Owners80.18%

Ins Owner ChangeN/A

Market Cap67.28M

Revenue(TTM)N/A

Net Income(TTM)25.93M

Analysts82.86

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	2.59
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.79
P/tB	0.79
EV/EBITDA	N/A

EPS(TTM)4.51

EY38.55%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-2.59

FCFYN/A

OCF(TTM)-2.59

OCFYN/A

SpS0

BVpS14.8

TBVpS14.8

PEG (NY)N/A

PEG (5Y)N/A

Graham Number38.76

Profitability

		Industry Rank	Sector Rank
ROA	29.93%
ROE	30.46%
ROCE	31.82%
ROIC	22.4%
ROICexc	29.58%
ROICexgc	29.58%
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-1.72%

ROA(5y)11.4%

ROE(3y)-1.65%

ROE(5y)11.58%

ROIC(3y)11.84%

ROIC(5y)16.55%

ROICexc(3y)17.54%

ROICexc(5y)53.02%

ROICexgc(3y)17.54%

ROICexgc(5y)53.04%

ROCE(3y)16.81%

ROCE(5y)23.52%

ROICexgc growth 3Y188.36%

ROICexgc growth 5YN/A

ROICexc growth 3Y188.36%

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	41.87
Quick Ratio	41.87
Altman-Z	23.54

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)415.47%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%231.05%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y217.89%

EBIT growth 3Y216.03%

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-279.65%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-279.65%

OCF growth 3YN/A

OCF growth 5YN/A

2INVEST AG / 2INV.DE FAQ

What is the fundamental rating for 2INV stock?

ChartMill assigns a fundamental rating of 4 / 10 to 2INV.DE.

Can you provide the valuation status for 2INVEST AG?

ChartMill assigns a valuation rating of 2 / 10 to 2INVEST AG (2INV.DE). This can be considered as Overvalued.

What is the profitability of 2INV stock?

2INVEST AG (2INV.DE) has a profitability rating of 4 / 10.

What is the financial health of 2INVEST AG (2INV.DE) stock?

The financial health rating of 2INVEST AG (2INV.DE) is 9 / 10.

2INVEST AG (2INV.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

2INVEST AG / 2INV.DE FAQ

What is the fundamental rating for 2INV stock?

Can you provide the valuation status for 2INVEST AG?

What is the profitability of 2INV stock?

What is the financial health of 2INVEST AG (2INV.DE) stock?